Moving targets in sodium channel blocker development: the case of raxatrigine: from a central NaV1.3 blocker via a peripheral NaV1.7 blocker to a less selective sodium channel blocker
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.